What Attracts Employees to Work on Site in Times of Increased Remote Working?
IEEE Software · 2025-01 · 42 (1) · 100-109
DOI: 10.1109/ms.2024.3375964 ↗Kurz gefasst
Fachartikel in der Zeitschrift IEEE Software, 2025-01. Verfasst von Darja Šmite und 2 weiteren Autor:innen. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 14 Literaturangaben.
Abstract (Originalsprache)
COVID-19 pandemic has irreversibly changed the attitude towards office presence. While previously remote workers were met with skepticism and distrust, today the same applies to companies prohibiting remote working. Albeit many workspaces are half empty. In this paper, we offer insights into the role of the office, corporate policies and actions regarding remote work in eight companies: Ericsson, Knowit, SpareBank 1 Utvikling, Spotify, Storebrand, Telenor, Company-X, Company-Y, and their sites in Sweden, Norway and the UK. Our findings are twofold. First, we found that companies indeed struggle with office presence and a large share of corporate space (35-67%) is underutilized. Second, we found that the main motivator for office presence is Connection and community, followed by Material offerings, Preference and Duty. Finally, we summarize actionable advice to promote onsite work, which is likely to help many other companies to rejuvenate life in their offices.
Zitieren
APA
Šmite, D., Klotins, E., & Moe, N. B. (2025). What Attracts Employees to Work on Site in Times of Increased Remote Working?. IEEE Software, 42(1), 100-109. https://doi.org/10.1109/ms.2024.3375964
Vancouver
Šmite D, Klotins E, Moe NB. What Attracts Employees to Work on Site in Times of Increased Remote Working?. IEEE Software. 2025;42(1):100-109. doi:10.1109/ms.2024.3375964
BibTeX
@article{mite2025,
author = {Šmite, Darja and Klotins, Eriks and Moe, Nils Brede},
title = {What Attracts Employees to Work on Site in Times of Increased Remote Working?},
journal = {IEEE Software},
year = {2025},
volume = {42},
number = {1},
pages = {100--109},
doi = {10.1109/ms.2024.3375964}
}
EUVIMED